Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Dem

71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also... | May 25, 2023

Related Keywords

Texas , United States , Tarrytown , American , Tammy Allen , Regeneron Velocimmune , Georged Yancopoulos , Hans Lee , L Andres Sirulnik , Myeloma Clinical Research , Clinical Sciences , Twitter , Regeneron Genetics Center , Exchange Commission , International Staging System , American Society Of Clinical Oncology , Regeneron Pharmaceuticals Inc , Nasdaq , Regeneron Velocimmune Technology , Drug Administration , University Of Texas Md Anderson Cancer Center , American Society Of Hematology , Clinical Oncology , Annual Meeting , Associate Professor , Multiple Myeloma Clinical Research , American Society , Senior Vice President , Fast Track Designation , Chief Scientific Officer George , Regeneron Genetics , Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Nc Stock Exchange , News , Information , Press Release , Objective , Response , Ith , F , Patients , Chieving , Very , Wood , Artial , Dr , Setter , It , The , Ecommended , 00 , G , Her , Few , Data , O , He , Shared , N , Mural , Session , Disco , Enefit Regn Us75886f1075 ,